Logo image of AGIO

AGIOS PHARMACEUTICALS INC (AGIO) Stock Fundamental Analysis

NASDAQ:AGIO - Nasdaq - US00847X1046 - Common Stock - Currency: USD

35  -2.22 (-5.96%)

After market: 35 0 (0%)

Fundamental Rating

5

Taking everything into account, AGIO scores 5 out of 10 in our fundamental rating. AGIO was compared to 551 industry peers in the Biotechnology industry. While AGIO has a great health rating, there are worries on its profitability. While showing a medium growth rate, AGIO is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

AGIO had negative earnings in the past year.
In the past year AGIO has reported a negative cash flow from operations.
The reported net income has been mixed in the past 5 years: AGIO reported negative net income in multiple years.
In the past 5 years AGIO always reported negative operating cash flow.
AGIO Yearly Net Income VS EBIT VS OCF VS FCFAGIO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B 1.5B

1.2 Ratios

The Return On Assets of AGIO (42.81%) is better than 99.46% of its industry peers.
With an excellent Return On Equity value of 45.41%, AGIO belongs to the best of the industry, outperforming 98.55% of the companies in the same industry.
Industry RankSector Rank
ROA 42.81%
ROE 45.41%
ROIC N/A
ROA(3y)-5.26%
ROA(5y)11.49%
ROE(3y)-6.92%
ROE(5y)4.3%
ROIC(3y)N/A
ROIC(5y)N/A
AGIO Yearly ROA, ROE, ROICAGIO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 100

1.3 Margins

AGIO's Profit Margin of 1798.26% is amongst the best of the industry. AGIO outperforms 99.82% of its industry peers.
AGIO's Gross Margin of 87.52% is amongst the best of the industry. AGIO outperforms 90.20% of its industry peers.
Industry RankSector Rank
OM N/A
PM (TTM) 1798.26%
GM 87.52%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AGIO Yearly Profit, Operating, Gross MarginsAGIO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K -1K -2K

More info and screens

9

2. Health

2.1 Basic Checks

AGIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for AGIO has been increased compared to 1 year ago.
The number of shares outstanding for AGIO has been reduced compared to 5 years ago.
AGIO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
AGIO Yearly Shares OutstandingAGIO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
AGIO Yearly Total Debt VS Total AssetsAGIO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

AGIO has an Altman-Z score of 13.25. This indicates that AGIO is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 13.25, AGIO belongs to the top of the industry, outperforming 90.02% of the companies in the same industry.
There is no outstanding debt for AGIO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 13.25
ROIC/WACCN/A
WACC10.85%
AGIO Yearly LT Debt VS Equity VS FCFAGIO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B 1.5B

2.3 Liquidity

AGIO has a Current Ratio of 18.50. This indicates that AGIO is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of AGIO (18.50) is better than 92.20% of its industry peers.
AGIO has a Quick Ratio of 17.93. This indicates that AGIO is financially healthy and has no problem in meeting its short term obligations.
AGIO has a Quick ratio of 17.93. This is amongst the best in the industry. AGIO outperforms 91.83% of its industry peers.
Industry RankSector Rank
Current Ratio 18.5
Quick Ratio 17.93
AGIO Yearly Current Assets VS Current LiabilitesAGIO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

5

3. Growth

3.1 Past

AGIO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -12.86%.
AGIO shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -24.03% yearly.
The Revenue has grown by 36.07% in the past year. This is a very strong growth!
EPS 1Y (TTM)-12.86%
EPS 3Y-24.03%
EPS 5YN/A
EPS Q2Q%-14.2%
Revenue 1Y (TTM)36.07%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%44.57%

3.2 Future

Based on estimates for the next years, AGIO will show a quite strong growth in Earnings Per Share. The EPS will grow by 17.59% on average per year.
The Revenue is expected to grow by 95.45% on average over the next years. This is a very strong growth
EPS Next Y-5.51%
EPS Next 2Y1.56%
EPS Next 3Y12.3%
EPS Next 5Y17.59%
Revenue Next Year21.16%
Revenue Next 2Y91.19%
Revenue Next 3Y111.66%
Revenue Next 5Y95.45%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
AGIO Yearly Revenue VS EstimatesAGIO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B 2B
AGIO Yearly EPS VS EstimatesAGIO Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 10 20

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

AGIO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year AGIO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AGIO Price Earnings VS Forward Price EarningsAGIO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AGIO Per share dataAGIO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20

4.3 Compensation for Growth

A more expensive valuation may be justified as AGIO's earnings are expected to grow with 12.30% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y1.56%
EPS Next 3Y12.3%

More info and screens

0

5. Dividend

5.1 Amount

AGIO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AGIOS PHARMACEUTICALS INC

NASDAQ:AGIO (8/1/2025, 8:19:30 PM)

After market: 35 0 (0%)

35

-2.22 (-5.96%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)07-31 2025-07-31/bmo
Earnings (Next)10-29 2025-10-29/bmo
Inst Owners103.93%
Inst Owner Change-0.09%
Ins Owners0.75%
Ins Owner Change1.37%
Market Cap2.03B
Analysts78.67
Price Target55.08 (57.37%)
Short Float %7.54%
Short Ratio6.65
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)15.64%
Min EPS beat(2)14.81%
Max EPS beat(2)16.46%
EPS beat(4)2
Avg EPS beat(4)-71.57%
Min EPS beat(4)-314.16%
Max EPS beat(4)16.46%
EPS beat(8)5
Avg EPS beat(8)-33.01%
EPS beat(12)9
Avg EPS beat(12)-7.11%
EPS beat(16)11
Avg EPS beat(16)-4.89%
Revenue beat(2)1
Avg Revenue beat(2)0.77%
Min Revenue beat(2)-11.26%
Max Revenue beat(2)12.79%
Revenue beat(4)1
Avg Revenue beat(4)-3.71%
Min Revenue beat(4)-11.26%
Max Revenue beat(4)12.79%
Revenue beat(8)2
Avg Revenue beat(8)-4.09%
Revenue beat(12)4
Avg Revenue beat(12)4.76%
Revenue beat(16)4
Avg Revenue beat(16)-19.55%
PT rev (1m)0%
PT rev (3m)-1.88%
EPS NQ rev (1m)-0.07%
EPS NQ rev (3m)4.11%
EPS NY rev (1m)0%
EPS NY rev (3m)3.28%
Revenue NQ rev (1m)-0.61%
Revenue NQ rev (3m)-4.31%
Revenue NY rev (1m)-2.75%
Revenue NY rev (3m)-15.42%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 54.74
P/FCF N/A
P/OCF N/A
P/B 1.38
P/tB 1.38
EV/EBITDA N/A
EPS(TTM)-7.34
EYN/A
EPS(NY)-6.78
Fwd EYN/A
FCF(TTM)-6.97
FCFYN/A
OCF(TTM)-6.93
OCFYN/A
SpS0.64
BVpS25.32
TBVpS25.32
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 42.81%
ROE 45.41%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 1798.26%
GM 87.52%
FCFM N/A
ROA(3y)-5.26%
ROA(5y)11.49%
ROE(3y)-6.92%
ROE(5y)4.3%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 41.38%
Cap/Sales 6.24%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 18.5
Quick Ratio 17.93
Altman-Z 13.25
F-Score4
WACC10.85%
ROIC/WACCN/A
Cap/Depr(3y)33.97%
Cap/Depr(5y)62.68%
Cap/Sales(3y)14.2%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-12.86%
EPS 3Y-24.03%
EPS 5YN/A
EPS Q2Q%-14.2%
EPS Next Y-5.51%
EPS Next 2Y1.56%
EPS Next 3Y12.3%
EPS Next 5Y17.59%
Revenue 1Y (TTM)36.07%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%44.57%
Revenue Next Year21.16%
Revenue Next 2Y91.19%
Revenue Next 3Y111.66%
Revenue Next 5Y95.45%
EBIT growth 1Y-12.05%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-15.24%
EBIT Next 3Y7.91%
EBIT Next 5YN/A
FCF growth 1Y-30.46%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-30.77%
OCF growth 3YN/A
OCF growth 5YN/A